Indaptus Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
INDP Nasdaq 2836 indaptusrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Indaptus Therapeutics, Inc.

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better - Sep 24th, 2026 9:23 pm
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 13th, 2026 5:00 am
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 15th, 2026 5:00 am
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - Dec 29th, 2025 5:00 am
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit - Nov 17th, 2025 6:00 am
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 12th, 2025 6:30 am